OBJECTIVE: Due to the heterogeneous biologic behavior of stage T1 bladder carcinomas, there is a need for new markers allowing to assess the prognosis more accurately. To our knowledge, there are no reports on studies investigating minichromosome maintenance protein 2 (MCM2) expression in bladder carcinomas. Thus, we investigated the prognostic value of MCM2 immunoreactivity in stage T1 bladder tumors. METHODS: Fifty-four tumors were analyzed using Biochip microarrays. Also p53 and Ki67 antigen expression were examined. Immunohistochemical scores were compared with the clinical outcome. RESULTS: During a median follow-up of 43 months, tumor recurrence was registered in 43 and progression to stage T2 in 19 patients. Kaplan-Meier curves demonstrated that high-level MCM2 expression was significantly associated with early tumor recurrence when using a cutoff of 60% (p=0.0035 by log-rank test), and with early tumor progression when using a cutoff of 20% (p=0.0454). There was no relationship (p=0.604) between MCM2 and p53, but a tendentious relationship (p=0.082) between MCM2 and Ki67 antigen expression. MCM2 (p=0.006), Ki67 antigen (p=0.035) and p53 expression (p=0.049) as well as tumor grade (p=0.026) and age (p=0.025) were found significantly associated with recurrence-free survival by univariate Cox regression analysis, among which only Ki67 antigen expression (p=0.015) and age (p=0.019) proved to be of independent predictive value by multivariate analysis. Concerning tumor progression, MCM2 expression was identified as the only predictive parameter by log-rank test, but it was not of independent predictive value by multivariate analysis (p=0.101). CONCLUSION: Our data suggest that MCM2 expression may bear some prognostic relevance in stage T1 bladder carcinomas.
OBJECTIVE: Due to the heterogeneous biologic behavior of stage T1 bladder carcinomas, there is a need for new markers allowing to assess the prognosis more accurately. To our knowledge, there are no reports on studies investigating minichromosome maintenance protein 2 (MCM2) expression in bladder carcinomas. Thus, we investigated the prognostic value of MCM2 immunoreactivity in stage T1 bladder tumors. METHODS: Fifty-four tumors were analyzed using Biochip microarrays. Also p53 and Ki67 antigen expression were examined. Immunohistochemical scores were compared with the clinical outcome. RESULTS: During a median follow-up of 43 months, tumor recurrence was registered in 43 and progression to stage T2 in 19 patients. Kaplan-Meier curves demonstrated that high-level MCM2 expression was significantly associated with early tumor recurrence when using a cutoff of 60% (p=0.0035 by log-rank test), and with early tumor progression when using a cutoff of 20% (p=0.0454). There was no relationship (p=0.604) between MCM2 and p53, but a tendentious relationship (p=0.082) between MCM2 and Ki67 antigen expression. MCM2 (p=0.006), Ki67 antigen (p=0.035) and p53 expression (p=0.049) as well as tumor grade (p=0.026) and age (p=0.025) were found significantly associated with recurrence-free survival by univariate Cox regression analysis, among which only Ki67 antigen expression (p=0.015) and age (p=0.019) proved to be of independent predictive value by multivariate analysis. Concerning tumor progression, MCM2 expression was identified as the only predictive parameter by log-rank test, but it was not of independent predictive value by multivariate analysis (p=0.101). CONCLUSION: Our data suggest that MCM2 expression may bear some prognostic relevance in stage T1 bladder carcinomas.
Authors: Charles A Fox; Lisa M Sapinoso; Hong Zhang; Wanghai Zhang; Howard L McLeod; Gina R Petroni; Tarun Mullick; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton; Steven M Powell Journal: Neoplasia Date: 2005-04 Impact factor: 5.715
Authors: Ellen C Obermann; Philip Went; Annette Zimpfer; Alexandar Tzankov; Peter J Wild; Robert Stoehr; Stefano A Pileri; Stephan Dirnhofer Journal: BMC Cancer Date: 2005-12-20 Impact factor: 4.430
Authors: Jun Yang; Nithya Ramnath; Kirsten B Moysich; Harold L Asch; Helen Swede; Sadir J Alrawi; Joel Huberman; Joseph Geradts; John S J Brooks; Dongfeng Tan Journal: BMC Cancer Date: 2006-08-01 Impact factor: 4.430
Authors: T J Dudderidge; S R McCracken; M Loddo; T R Fanshawe; J D Kelly; D E Neal; H Y Leung; G H Williams; K Stoeber Journal: Br J Cancer Date: 2007-04-03 Impact factor: 7.640
Authors: John D Kelly; Tim J Dudderidge; Alex Wollenschlaeger; Odu Okoturo; Keith Burling; Fiona Tulloch; Ian Halsall; Teresa Prevost; Andrew Toby Prevost; Joana C Vasconcelos; Wendy Robson; Hing Y Leung; Nikhil Vasdev; Robert S Pickard; Gareth H Williams; Kai Stoeber Journal: PLoS One Date: 2012-07-09 Impact factor: 3.240
Authors: H Gakiopoulou; P Korkolopoulou; G Levidou; I Thymara; A Saetta; C Piperi; N Givalos; I Vassilopoulos; K Ventouri; A Tsenga; A Bamias; M-A Dimopoulos; E Agapitos; E Patsouris Journal: Br J Cancer Date: 2007-10-16 Impact factor: 7.640